# A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

> **NCT01461993** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 2499 (actual)

## Conditions studied

- Vaccines
- Meningococcal Vaccines

## Interventions

- **BIOLOGICAL:** rLP2086 and Gardasil
- **BIOLOGICAL:** rLP2086
- **BIOLOGICAL:** Gardasil

## Key facts

- **NCT ID:** NCT01461993
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-28
- **Primary completion:** 2013-07-06
- **Final completion:** 2013-07-06
- **Target enrollment:** 2499 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01461993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01461993, "A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01461993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*